Geron on track for imetelstat myelodysplastic syndromes NDA submission in June

• Geron (NASDAQ:GERN) said that its planned New Drug Application for imetelstat for lower risk myelodysplastic syndromes is on track for submission in June.
• The company noted that an abstract of phase 3 data that is supporting the application was accepted for an oral presentation at the American Society of Clinical Oncology Annual Meeting next month.
• Geron (GERN) is eying a potential US launch in H1 2024.
• Top-line data on imetelstat released in January showed it met its primary endpoint and a key secondary endpoint.

More on Geron

• Geron: Where Things Stand With Several Milestones On The Horizon

• Geron's Imetelstat Could Find Its Place In MDS Treatment, Yet Prudence Is Advised